当前位置: 首页 >> 检索结果
21. Faecal microbial transfer and complex carbohydrates mediate protection against COPD.
作者: Kurtis F Budden.;Shakti D Shukla.;Kate L Bowerman.;Annalicia Vaughan.;Shaan L Gellatly.;David L A Wood.;Nancy Lachner.;Sobia Idrees.;Saima Firdous Rehman.;Alen Faiz.;Vyoma K Patel.;Chantal Donovan.;Charlotte A Alemao.;Sj Shen.;Nadia Amorim.;Rajib Majumder.;Kanth S Vanka.;Jazz Mason.;Tatt Jhong Haw.;Bree Tillet.;Michael Fricker.;Simon Keely.;Nicole Hansbro.;Gabrielle T Belz.;Jay Horvat.;Thomas Ashhurst.;Caryn van Vreden.;Helen McGuire.;Barbara Fazekas de St Groth.;Nicholas J C King.;Ben Crossett.;Stuart J Cordwell.;Lorenzo Bonaguro.;Joachim L Schultze.;Emma E Hamilton-Williams.;Elizabeth Mann.;Samuel C Forster.;Matthew A Cooper.;Leopoldo N Segal.;Sanjay H Chotirmall.;Peter Collins.;Rayleen Bowman.;Kwun M Fong.;Ian A Yang.;Peter A B Wark.;Paul G Dennis.;Philip Hugenholtz.;Philip M Hansbro.
来源: Gut. 2024年73卷5期751-769页
Chronic obstructive pulmonary disease (COPD) is a major cause of global illness and death, most commonly caused by cigarette smoke. The mechanisms of pathogenesis remain poorly understood, limiting the development of effective therapies. The gastrointestinal microbiome has been implicated in chronic lung diseases via the gut-lung axis, but its role is unclear.
22. Proton pump inhibitors alter gut microbiota by promoting oral microbiota translocation: a prospective interventional study.
作者: Xue Xiao.;Xian Zhang.;Jin Wang.;Yuqiang Liu.;Hailin Yan.;Xiaocun Xing.;Jinlin Yang.
来源: Gut. 2024年73卷7期1098-1109页
The mechanism by which proton pump inhibitors (PPIs) alter gut microbiota remains to be elucidated. We aimed to learn whether PPI induced gut microbiota alterations by promoting oral microbial translocation.
23. Short-duration selective decontamination of the digestive tract infection control does not contribute to increased antimicrobial resistance burden in a pilot cluster randomised trial (the ARCTIC Study).
作者: Iain Robert Louis Kean.;John A Clark.;Zhenguang Zhang.;Esther Daubney.;Deborah White.;Paloma Ferrando-Vivas.;Gema Milla.;Brian Cuthbertson.;John Pappachan.;Nigel Klein.;Paul Mouncey.;Kathy Rowan.;John Myburgh.;Theodore Gouliouris.;Stephen Baker.;Julian Parkhill.;Nazima Pathan.; Arctic Research Team.
来源: Gut. 2024年73卷6期910-921页
Selective decontamination of the digestive tract (SDD) is a well-studied but hotly contested medical intervention of enhanced infection control. Here, we aim to characterise the changes to the microbiome and antimicrobial resistance (AMR) gene profiles in critically ill children treated with SDD-enhanced infection control compared with conventional infection control.
24. Standardised training for endoscopic mucosal resection of large non-pedunculated colorectal polyps to reduce recurrence (*STAR-LNPCP study): a multicentre cluster randomised trial.
作者: Lonne W T Meulen.;Roel M M Bogie.;Peter D Siersema.;Bjorn Winkens.;Marije S Vlug.;Frank H J Wolfhagen.;Martine Baven-Pronk.;Michael van der Voorn.;Matthijs P Schwartz.;Lauran Vogelaar.;Wouter H de Vos Tot Nederveen Cappel.;Tom C J Seerden.;Wouter L Hazen.;Ruud W M Schrauwen.;Lorenza Alvarez Herrero.;Ramon-Michel M Schreuder.;Annick B van Nunen.;Esther Stoop.;Gijs J de Bruin.;Philip Bos.;Willem A Marsman.;Edith Kuiper.;Marc de Bièvre.;Yasser A Alderlieste.;Robert Roomer.;John Groen.;Marloes Bargeman.;Monique E van Leerdam.;Linda Roberts-Bos.;Femke Boersma.;Karsten Thurnau.;Roland S de Vries.;Jos M Ramaker.;Frank P Vleggaar.;Rogier J de Ridder.;María Pellisé.;Michael J Bourke.;Ad A M Masclee.;Leon M G Moons.
来源: Gut. 2024年73卷5期741-750页
Endoscopic mucosal resection (EMR) is the preferred treatment for non-invasive large (≥20 mm) non-pedunculated colorectal polyps (LNPCPs) but is associated with an early recurrence rate of up to 30%. We evaluated whether standardised EMR training could reduce recurrence rates in Dutch community hospitals.
25. Treatment of non-constipated irritable bowel syndrome with the histamine 1 receptor antagonist ebastine: a randomised, double-blind, placebo-controlled trial.
作者: Lisse Decraecker.;Danny De Looze.;David P Hirsch.;Heiko De Schepper.;Joris Arts.;Philip Caenepeel.;Albert J Bredenoord.;Jeroen Kolkman.;Koen Bellens.;Kim Van Beek.;Fedrica Pia.;Willy Peetermans.;Tim Vanuytsel.;Alexandre Denadai-Souza.;Ann Belmans.;Guy Boeckxstaens.
来源: Gut. 2024年73卷3期459-469页
We evaluated the histamine 1 receptor antagonist ebastine as a potential treatment for patients with non-constipated irritable bowel syndrome (IBS) in a randomised, placebo-controlled phase 2 study.
26. Blood-based colorectal cancer screening in an integrated health system: a randomised trial of patient adherence.
作者: Gloria D Coronado.;Charisma L Jenkins.;Elizabeth Shuster.;Cheryl Johnson.;David Amy.;Jennifer Cook.;Samantha Sahnow.;Jamilyn M Zepp.;Rajasekhara Mummadi.
来源: Gut. 2024年73卷4期622-628页
We evaluated whether people who had not completed a faecal immunochemical test (FIT) for colorectal cancer (CRC) screening would complete a blood-based testing option if offered one during health encounters. Blood-based screening tests for CRC could add to the total number of people screened for CRC by providing another testing alternative.
27. Endoscopic variceal ligation versus propranolol for the primary prevention of oesophageal variceal bleeding in patients with hepatocellular carcinoma: an open-label, two-centre, randomised controlled trial.
作者: Tsung-Chieh Yang.;Wen-Chi Chen.;Ming-Chih Hou.;Ping-Hsien Chen.;Pei-Chang Lee.;Chung-Yu Chang.;Hsiao-Sheng Lu.;Yu-Jen Chen.;Shao-Jung Hsu.;Hui-Chun Huang.;Jiing-Chyuan Luo.;Yi-Hsiang Huang.;Fa-Yauh Lee.
来源: Gut. 2024年73卷4期682-690页
This randomised trial aimed to address whether endoscopic variceal ligation (EVL) or propranolol (PPL) is more effective at preventing initial oesophageal variceal bleeding (EVB) in patients with hepatocellular carcinoma (HCC).
28. 10-year follow-up results of the European Achalasia Trial: a multicentre randomised controlled trial comparing pneumatic dilation with laparoscopic Heller myotomy.
作者: Guy Boeckxstaens.;Stefanie Elsen.;Ann Belmans.;Vito Annese.;Albert J Bredenoord.;Olivier R Busch.;Mario Costantini.;Uberto Fumagalli.;André J P M Smout.;Jan Tack.;Tim Vanuytsel.;Giovanni Zaninotto.;Renato Salvador.
来源: Gut. 2024年73卷4期582-589页
As achalasia is a chronic disorder, long-term follow-up data comparing different treatments are essential to select optimal clinical management. Here, we report on the 10-year follow-up of the European Achalasia Trial comparing endoscopic pneumodilation (PD) with laparoscopic Heller myotomy (LHM).
29. Compared to histamine-2 receptor antagonist, proton pump inhibitor induces stronger oral-to-gut microbial transmission and gut microbiome alterations: a randomised controlled trial.
作者: Jiaying Zhu.;Chuqing Sun.;Min Li.;Guoru Hu.;Xing-Ming Zhao.;Wei-Hua Chen.
来源: Gut. 2024年73卷7期1087-1097页
We aim to compare the effects of proton pump inhibitors (PPIs) and histamine-2 receptor antagonists (H2RAs) on the gut microbiota through longitudinal analysis.
30. Dupilumab demonstrated efficacy and was well tolerated regardless of prior use of swallowed topical corticosteroids in adolescent and adult patients with eosinophilic oesophagitis: a subgroup analysis of the phase 3 LIBERTY EoE TREET study.
作者: Albert J Bredenoord.;Evan S Dellon.;Ikuo Hirano.;Alfredo J Lucendo.;Christoph Schlag.;Xian Sun.;Lila Glotfelty.;Leda Mannent.;Jennifer Maloney.;Elizabeth Laws.;Eric Mortensen.;Arsalan Shabbir.
来源: Gut. 2024年73卷3期398-406页
To assess the effect of long-term dupilumab on histological, symptomatic and endoscopic aspects of eosinophilic oesophagitis (EoE) in adolescent and adult patients with and without prior use of swallowed topical corticosteroids (STC) or prior inadequate response, intolerance or contraindication to STC.
31. Prebiotic diet changes neural correlates of food decision-making in overweight adults: a randomised controlled within-subject cross-over trial.
作者: Evelyn Medawar.;Frauke Beyer.;Ronja Thieleking.;Sven-Bastiaan Haange.;Ulrike Rolle-Kampczyk.;Madlen Reinicke.;Rima Chakaroun.;Martin von Bergen.;Michael Stumvoll.;Arno Villringer.;A Veronica Witte.
来源: Gut. 2024年73卷2期298-310页
Animal studies suggest that prebiotic, plant-derived nutrients could improve homoeostatic and hedonic brain functions through improvements in microbiome-gut-brain communication. However, little is known if these results are applicable to humans. Therefore, we tested the effects of high-dosed prebiotic fibre on reward-related food decision-making in a randomised controlled within-subject cross-over study and assayed potential microbial and metabolic markers.
32. Optimal measurement of gastric emptying of solids in gastroparesis or functional dyspepsia: evidence to establish standard test.
作者: Michael Camilleri.;Ting Zheng.;Kia Vosoughi.;Camille Lupianez-Merly.;Deborah Eckert.;Irene Busciglio.;Duane Burton.;Saam Dilmaghani.
来源: Gut. 2023年72卷12期2241-2249页
Symptoms in gastroparesis (Gp) and functional dyspepsia (FD) overlap; using egg protein substitute to measure gastric emptying of solids (GES), ~40% of patients are reclassified from Gp to FD, and vice versa. Our aim was to assess inter-individual and intra-individual coefficients of variation (COV) in GES in symptomatic patients with Gp or FD with documented slow or normal GES, respectively.
33. Endoluminal radiofrequency ablation in patients with malignant biliary obstruction: a randomised trial.
作者: Jana Jarosova.;Lea Zarivnijova.;Ivana Cibulkova.;Jan Mares.;Peter Macinga.;Alzbeta Hujova.;Premysl Falt.;Ondrej Urban.;Jan Hajer.;Julius Spicak.;Tomas Hucl.
来源: Gut. 2023年72卷12期2286-2293页
Endoluminal radiofrequency ablation (RFA) has been promoted as palliative treatment for patients with cholangiocarcinoma (CCA) and pancreatic ductal adenocarcinoma (PDAC) in order to improve biliary drainage and eventually prolong survival. No high level evidence is, however, available on this technique.
34. Clinical care pathway to detect advanced liver disease in patients with type 2 diabetes through automated fibrosis score calculation and electronic reminder messages: a randomised controlled trial.
作者: Xinrong Zhang.;Terry Cheuk-Fung Yip.;Grace Lai-Hung Wong.;Wei-Xuan Leow.;Lilian Yan Liang.;Lee-Ling Lim.;Guanlin Li.;Luqman Ibrahim.;Huapeng Lin.;Jimmy Che To Lai.;Angel Mei-Ling Chim.;Henry Lik Yuen Chan.;Alice Pik-Shan Kong.;Wah Kheong Chan.;Vincent Wai-Sun Wong.
来源: Gut. 2023年72卷12期2364-2371页
We aimed to test the hypothesis that automated fibrosis score calculation and electronic reminder messages could increase the detection of advanced liver disease in patients with type 2 diabetes.
35. Mepolizumab for treatment of adolescents and adults with eosinophilic oesophagitis: a multicentre, randomised, double-blind, placebo-controlled clinical trial.
作者: Evan S Dellon.;Kathryn A Peterson.;Benjamin L Mitlyng.;Alina Iuga.;Christine E Bookhout.;Lindsay M Cortright.;Kacie B Walker.;Timothy S Gee.;Sarah J McGee.;Brenderia A Cameron.;Joseph A Galanko.;John T Woosley.;Swathi Eluri.;Susan E Moist.;Ikuo Hirano.
来源: Gut. 2023年72卷10期1828-1837页
We aimed to determine whether mepolizumab, an anti-IL-5 antibody, was more effective than placebo for improving dysphagia symptoms and decreasing oesophageal eosinophil counts in eosinophilic oesophagitis (EoE).
36. Technical performance and diagnostic yield of motorised spiral enteroscopy compared with single-balloon enteroscopy in suspected Crohn's disease: a randomised controlled, open-label study (the MOTOR-CD trial).
作者: Partha Pal.;Mohan Ramchandani.;Rupa Banerjee.;Piyush Viswakarma.;Aniruddha Pratap Singh.;Manohar Reddy.;Hardik Rughwani.;Rajendra Patel.;Anuradha Sekaran.;Swathi Kanaganti.;Santosh Darisetty.;Zaheer Nabi.;Jagadish Singh.;Rajesh Gupta.;Sundeep Lakhtakia.;Rebala Pradeep.;G Venkat Rao.;Manu Tandan.;D Nageshwar Reddy.
来源: Gut. 2023年72卷10期1866-1874页
Recent studies have shown that motorised spiral enteroscopy (MSE) enables deeper and total small bowel evaluation compared with single-balloon enteroscopy (SBE) in suspected Crohn's disease (CD) when analysed per procedure. However, no randomised controlled study has compared bidirectional MSE with bidirectional SBE in suspected CD.
37. Gut microbiome modulates the effects of a personalised postprandial-targeting (PPT) diet on cardiometabolic markers: a diet intervention in pre-diabetes.
作者: Orly Ben-Yacov.;Anastasia Godneva.;Michal Rein.;Smadar Shilo.;Maya Lotan-Pompan.;Adina Weinberger.;Eran Segal.
来源: Gut. 2023年72卷8期1486-1496页
To explore the interplay between dietary modifications, microbiome composition and host metabolic responses in a dietary intervention setting of a personalised postprandial-targeting (PPT) diet versus a Mediterranean (MED) diet in pre-diabetes.
38. Long versus short peroral endoscopic myotomy for the treatment of achalasia: results of a non-inferiority randomised controlled trial.
作者: Pietro Familiari.;Federica Borrelli de Andreis.;Rosario Landi.;Francesca Mangiola.;Ivo Boskoski.;Andrea Tringali.;Vincenzo Perri.;Guido Costamagna.
来源: Gut. 2023年72卷8期1442-1450页
Peroral endoscopic myotomy (POEM) has become standard treatment for achalasia with comparable efficacy to surgery. In most of published series, the length of myotomy is 12-13 cm. Shorter cuts could have the advantage of shorter procedure time and possibly reduced gastro-oesophageal reflux disease (GORD) rate.
39. Standardisation of EUS-guided FNB technique for molecular profiling in pancreatic cancer: results of a randomised trial.
作者: Ji Young Bang.;Nirag Jhala.;Anjali Seth.;Konrad Krall.;Udayakumar Navaneethan.;Robert Hawes.;Charles Melbern Wilcox.;Shyam Varadarajulu.
来源: Gut. 2023年72卷7期1255-1257页 40. Three double-dose reinforced hepatitis B revaccination scheme for patients with cirrhosis unresponsive to the standard regimen: an open-label randomised clinical trial.
作者: Álvaro Giráldez-Gallego.;Elisa Del Pilar Rodríguez-Seguel.;Raquel Valencia-Martín.;Áurea Morillo-García.;Celia Salamanca-Rivera.;Ricardo Ruiz-Pérez.;María Cuaresma-Duque.;Clara Rosso-Fernández.;María Teresa Ferrer-Ríos.;José Manuel Sousa-Martín.;Juan Manuel Praena-Fernández.;Trinidad Desongles-Corrales.;Aitana Rodríguez-Pérez.;Francisco Camino-Durán.;Antonia Gasch-Illescas.;Javier Ampuero-Herrojo.;Juan Manuel Pascasio-Acevedo.
来源: Gut. 2023年73卷1期166-174页
We aimed to compare the response rates between two different hepatitis B virus vaccination schedules for cirrhotic subjects who were non-responders to the first three 40 µg doses (month 0-1-2), and identify factors associated with the final response.
|